Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NR3C1 Clear all
Not yet recruiting Phase 1 Interventional

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

NCT07579208
View directory record Official record
Conditions
Phase 1, NK Cell, IL13Ra, EGFRvIII, Chimera Antigen Receptor (CAR), NR3C1, Recurrent Glioblastoma
Interventions
NK Cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

NCT03697109
View directory record Official record
Conditions
Cushing Syndrome
Interventions
Relacorilant, Placebo
Drug · Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Los Angeles, California • Torrance, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Jul 21, 2026, 4:00 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03437941
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
Exicorilant, Enzalutamide, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • Detroit, Michigan • Basking Ridge, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder

NCT00039715
View directory record Official record
Conditions
Post-Traumatic Stress Disorders, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 4:00 PM EDT
Recruiting Phase 2 Interventional

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

NCT05726292
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Recruiting Phase 1 Interventional

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

NCT04991870
View directory record Official record
Conditions
Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma
Interventions
Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Resection
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Meal Patterning on Weight Loss With Changes to Body Comp, Muscle and Metabolic Health

NCT02066948
View directory record Official record
Conditions
Body Composition, Beneficial, Paresis, Impaired Glucose Tolerance
Interventions
wt loss, meal pattern, even, skew
Other · Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
19 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Jul 21, 2026, 4:00 PM EDT
Terminated Phase 2 Interventional Results available

Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)

NCT01212588
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
mifepristone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 64 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jul 21, 2026, 4:00 PM EDT
Completed No phase listed Observational

C-myc Biomarker Study for Diabetic Foot Ulcers

NCT04591691
View directory record Official record
Conditions
Diabetes, Diabetic Foot, Diabetic Foot Ulcer, Diabetic Wound
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

NCT02645253
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease COPD
Interventions
AZD7594 inhalation powder (200 μg), AZD7594 inhalation powder (400 μg), AZD7594 pressurized inhalation suspension (200 μg), AZD7594 placebo inhalation powder, AZD7594 placebo pressurized inhalation suspension
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Jul 21, 2026, 4:00 PM EDT
Recruiting Phase 2 Interventional

Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)

NCT04452500
View directory record Official record
Conditions
PTSD
Interventions
CORT108297, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 69 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Tuscaloosa, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

NCT02762981
View directory record Official record
Conditions
Solid Tumors
Interventions
Relacorilant with nab-paclitaxel
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Results available

Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism

NCT01990560
View directory record Official record
Conditions
Mild Hypercortisolism
Interventions
Mifepristone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

NCT03622112
View directory record Official record
Conditions
Asthma
Interventions
AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
21
States / cities
Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Jul 21, 2026, 4:00 PM EDT
Withdrawn Not applicable Interventional

Impact of Exercise on Body Composition in Premature Infants

NCT01386190
View directory record Official record
Conditions
Body Composition, Beneficial
Interventions
Exercise/Social Behavioral
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
29 Weeks to 34 Weeks
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Jul 21, 2026, 4:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease

NCT01143493
View directory record Official record
Conditions
Glucose Homeostasis, Protein Metabolism, Lipid Metabolism, Respiratory Function, Connective Tissue Metabolism
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

NCT02012296
View directory record Official record
Conditions
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
enzalutamide, mifepristone, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Jul 21, 2026, 4:00 PM EDT
Withdrawn No phase listed Observational

Breast Cancer BRCA1 Carriers: a Pilot Study

NCT05062174
View directory record Official record
Conditions
BRCA1 Mutation, High-grade Serous Ovarian Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
Mifepristone 200 MG, Prophylactic mastectomy
Drug · Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma

NCT03976869
View directory record Official record
Conditions
Asthma
Interventions
AZD7594
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Rolling Hills Estates, California • Miami, Florida • Miami Lakes, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Breakfast Meal Replacement

NCT02482545
View directory record Official record
Conditions
Body Composition, Beneficial, Basal Metabolic Rate, Satiety, Overweight, Obese
Interventions
Meal replacement
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers

NCT02767089
View directory record Official record
Conditions
Healthy Adults
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CrossFit Exercise to Improve Glucose Control for Overweight and Obese Adults

NCT02185872
View directory record Official record
Conditions
Hyperglycemia
Interventions
High-Intensity Functional Training, Aerobic and Resistance Training
Other
Lead sponsor
Kansas State University
Other
Eligibility
18 Years to 40 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 1 Interventional

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

NCT04373265
View directory record Official record
Conditions
Adrenocortical Carcinoma
Interventions
Relacorilant, Pembrolizumab
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Stanford, California • Tampa, Florida • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 1 Interventional

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

NCT03674814
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, Relacorilant
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 21, 2026, 4:00 PM EDT